IT1229517B - Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. - Google Patents

Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Info

Publication number
IT1229517B
IT1229517B IT8919261A IT1926189A IT1229517B IT 1229517 B IT1229517 B IT 1229517B IT 8919261 A IT8919261 A IT 8919261A IT 1926189 A IT1926189 A IT 1926189A IT 1229517 B IT1229517 B IT 1229517B
Authority
IT
Italy
Prior art keywords
acid
disorders
treatment
preparation
pharmaceutically acceptable
Prior art date
Application number
IT8919261A
Other languages
English (en)
Italian (it)
Other versions
IT8919261A0 (it
Inventor
Cristina Le Grazie
Original Assignee
Bioresearch Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresearch Spa filed Critical Bioresearch Spa
Publication of IT8919261A0 publication Critical patent/IT8919261A0/it
Priority to IT8919261A priority Critical patent/IT1229517B/it
Priority to ES90101570T priority patent/ES2055175T3/es
Priority to AT90101570T priority patent/ATE88895T1/de
Priority to DE9090101570T priority patent/DE69001493T2/de
Priority to EP90101570A priority patent/EP0382019B1/en
Priority to DK90101570.1T priority patent/DK0382019T3/da
Priority to JP2019369A priority patent/JPH0757727B2/ja
Application granted granted Critical
Publication of IT1229517B publication Critical patent/IT1229517B/it
Priority to GR920403210T priority patent/GR3007790T3/el
Priority to US08/386,188 priority patent/US5538734A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IT8919261A 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. IT1229517B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
EP90101570A EP0382019B1 (en) 1989-01-31 1990-01-26 Use of 5-methyltetrahydrofolic acid, of 5-formyl-tetrahydrofolic acid and of their pharmaceutically acceptable salts for the preparation of controlled release pharmaceutical compositions suitable for the use in the therapy of depressive disturbances, and pharmaceutical compositions thus prepared
AT90101570T ATE88895T1 (de) 1989-01-31 1990-01-26 Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
DE9090101570T DE69001493T2 (de) 1989-01-31 1990-01-26 Verwendung von 5-methyltetrahydrofolsaeure, 5-formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
ES90101570T ES2055175T3 (es) 1989-01-31 1990-01-26 Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co
DK90101570.1T DK0382019T3 (da) 1989-01-31 1990-01-26 Anvendelse af 5-methyltetrahydrofolsyre, af 5-formyltetrahydrofolsyre og af deres farmaceutisk acceptable salte til fremstilling af farmaceutiske præparater med reguleret frigivelse egnet til anvendelse ved terapi af depressive forstyrrelser, og således fremstillede farmaceutiske præparater
JP2019369A JPH0757727B2 (ja) 1989-01-31 1990-01-31 抑うつ障害の治療用に適した制御放出製薬組成物
GR920403210T GR3007790T3 (enExample) 1989-01-31 1993-05-06
US08/386,188 US5538734A (en) 1989-01-31 1995-02-09 5-methyltetrahydrofolic acid, 5-formyl-tetrahydrofolic acid and their pharmaceutically acceptable salts for use in the therapy of depressive disturbances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Publications (2)

Publication Number Publication Date
IT8919261A0 IT8919261A0 (it) 1989-01-31
IT1229517B true IT1229517B (it) 1991-09-03

Family

ID=11156204

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Country Status (9)

Country Link
US (1) US5538734A (enExample)
EP (1) EP0382019B1 (enExample)
JP (1) JPH0757727B2 (enExample)
AT (1) ATE88895T1 (enExample)
DE (1) DE69001493T2 (enExample)
DK (1) DK0382019T3 (enExample)
ES (1) ES2055175T3 (enExample)
GR (1) GR3007790T3 (enExample)
IT (1) IT1229517B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
CA2243981C (en) * 1996-01-31 2005-09-06 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
ES2292238T3 (es) * 1998-04-24 2008-03-01 Scarista Limited Tratamiento de la depresion y preparaciones farmaceuticas para el mismo.
EP1102578A4 (en) * 1998-08-03 2005-05-18 Epigenesis Pharmaceuticals Inc NEW ANALGICAL, ANTIINFLAMMATORY AND WOUND HEALING ACTIVE SUBSTANCE
WO2000023089A1 (en) * 1998-10-19 2000-04-27 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
AU6202299A (en) * 1998-10-30 2000-05-22 Merck Patent Gmbh Compositions for the treatment and prevention of neurological and pathopsychological diseases
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
EP1349554A2 (en) * 2000-12-14 2003-10-08 Tufts University Compositions and methods for treating an arthritic condition
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
JP2005530820A (ja) * 2002-06-17 2005-10-13 エピジェネシス ファーマシューティカルズ リミティド ライアビリティー カンパニー 二水和デヒドロエピアンドロステロン及びその組成物を用いた喘息又は慢性閉塞性肺疾患の治療方法
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
WO2011006147A1 (en) * 2009-07-10 2011-01-13 Scott Iii Linzy O Methods and compositions for treating thyroid-related medical conditions with reduced folates
US8372451B2 (en) * 2010-02-12 2013-02-12 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
HUE068578T2 (hu) 2017-03-31 2025-01-28 Merck Patent Gmbh 5-Metil-(6S)-tetrahidrofolsav kristályos nátriumsója

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572137A (en) * 1977-02-22 1980-07-23 Bioresearch Sas Del Dr Livio C Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
GB2072504B (en) * 1980-03-27 1983-10-26 Coppen A J Pharmaceutical compositions
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.

Also Published As

Publication number Publication date
US5538734A (en) 1996-07-23
GR3007790T3 (enExample) 1993-08-31
DK0382019T3 (da) 1993-06-07
IT8919261A0 (it) 1989-01-31
DE69001493D1 (de) 1993-06-09
JPH0757727B2 (ja) 1995-06-21
EP0382019B1 (en) 1993-05-05
ES2055175T3 (es) 1994-08-16
ATE88895T1 (de) 1993-05-15
JPH02240021A (ja) 1990-09-25
DE69001493T2 (de) 1993-08-26
EP0382019A1 (en) 1990-08-16

Similar Documents

Publication Publication Date Title
IT1229517B (it) Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1229203B (it) Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PT1235826E (pt) Acrilamidas de quinuclidina
EP0379806A3 (en) Pyrimidines and their pharmaceutical acceptable salts, and their use as medicines
FI862011A0 (fi) Terapeutiska nukleosider.
NZ232734A (en) 19-nor vitamin d derivatives and pharmaceutical compositions
PT1427708E (pt) Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os
PT83080A (en) Process for the preparation of biciclic naphthyridine compounds or analogs and their salts soluates hydrates and esters
MX10059A (es) Procedimiento para la preparacion de antagonistas de leucotrienos novedosos y producto obtenido
DE69005860D1 (de) Verwendung von 5'-Deoxy-5'-methylthioadenosin S-adenosylmethionin und dessen Salzen zur Herstellung von Seborrhea vermindernden Arzneimitteln.
MY108482A (en) Compounds.
GB9109972D0 (en) Therapeutic compounds
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
IT1261213B (it) Procedimento per la preparazione di sali dell'acido clavulanico.
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
ES537205A0 (es) Procedimiento para preparar derivados de purina
IL111580A (en) Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
NZ228182A (en) Substituted 4,5,6,7-tetrahydroisothiazolo(4,5-c) pyridine derivatives and pharmaceutical compositions; methods for preparation
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds
IT1232352B (it) Derivati dell'acido chinurenico ad attivita' sul sistema nervoso centrale, loro preparazione e relative composizioni farmaceutiche
GR3033394T3 (en) New alkaloid derivatives, their use and pharmaceutical formulations containing them.
IT8822545A0 (it) Impiego dell'acido 5-metiltetraidrofolico, dell'acido 5-formiltetraidrofolico, dell'acido folico e dei loro sali in associazione con ferro per la preparazione di composizioni farmaceutiche adatte nel ripristino delle scorte organiche di ferro e composizioni farmaceutiche reelative
GR78670B (enExample)
IT8721255A0 (it) 2 tiolpropionil arginine, loro sali, procedimento per la loro preparazione e relative composizioni farmaceutiche.
EP0294814A3 (en) Treating agents for renal diseases

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19940203